SlideShare a Scribd company logo
1 of 66
FBW
             11-12-2012




Wim Van Criekinge
Inhoud Lessen: Bioinformatica




                                GEEN LES
GEEN
LES
OP 4
DECEMBER
Examen
         <html>
         <title>Examen Bioinformatica</title>
         <center>
         <head>
         <script>
         rnd.today=new Date();
         rnd.seed=rnd.today.getTime();
         function rnd() {
               rnd.seed = (rnd.seed*9301+49297) % 233280;
               return rnd.seed/(233280.0);
         };
         function rand(number) {
               return Math.ceil(rnd()*number);
         };
         </SCRIPT>
         </head>
         <body bgcolor="#FFFFFF" text="#00FF00" link="#00FF00">
         <script language="JavaScript">
         document.write('<table>');
         document.write('<tr>');
         document.write('<td><a href="index.html" ><img border=0 src="' + rand(713)   + '.jpg" width="520"
                height="360"></a></td>');
         rand(98);
         document.write('<td><a href="index.html" ><img border=0 src="' + rand(713)   + '.jpg" width="520"
                height="360"></a></td>');
         rand(98);
         document.write('<td><a href="index.html" ><img border=0 src="' + rand(713)   + '.jpg" width="520"
                height="360"></a></td>');
         rand(98);
         document.write('<td><a href="index.html" ><img border=0 src="' + rand(713)   + '.jpg" width="520"
                height="360"></a></td>');
         rand(98);
Comparative Genomics: The biological Rosetta


                           • The keywords can be
                                –   genome structure
                                –   gene-organisation
                                –   known promoter regions
                                –   known critical amino acid residues.
                           • Combination of functional
                             modelorganism knowledge
                           • Structure-function
                           • Identify similar areas of biology
                           • Identify orthologous pathways (might
                             have different endpoints)
Example: Agro


                                           Sequence Genome




                                                  Known “lethal” genes
                                                  from worm, drosphila




                Filter for drugability”,
                tractibility & novelty
Example: Extremophiles


Look for species                          Sequence Genome
with interesting
phenotypes




Functional Foods
Convert Highly Energetic Monosaccharides to Dextrane

Washing Powder additives                                       Known lipases




                                                            Filter for
                                                            “workable”lipases
                                                            at 90º C

                   Clone and produce in large quantities
Drug Discovery: Design new drugs by computer?




                 Problem: pipeline cost rise linear, NCE steady
                 Money: bypassing difficult, work on attrition

                 Every step requires specific computational tools
Drug Discovery: What is a drug ?

                         • Drugs are generally defined as molecules which
                           affect biological processes.
                         • In order to be effective, the molecule must be
                           present in the body at an adequate concentration
                           for it to act at the specific site in the body where
                           it can exert its effect.
                         • Additionally, the molecule must be safe -- that
                           is, metabolized and eliminated from the body
                           without causing injury.
                         • Assumption: next 50 years still a big market in
                           small chemical entities which can be
                           administered orally in form of a pill (in contrast
                           to antibodies) or gene therapy …
• Taxol a drug which is an unmodified natural
  compound, is the exception
• Most drugs require “work” -> need for target
  driven pipeline
• Humane genome is available so all target are
  identified
• How to validate (within a given disease area) ?
Drug Discovery: What is a target ?

                          • target - a molecule (often a protein) that is instrumental
                            to a disease process (though not necessarily directly
                            involved), which may be targeted with a potential
                            therapeutic.
                          • target identification - identifying a molecule (often a
                            protein) that is instrumental to a disease process (though
                            not necessarily directly involved), with the intention of
                            finding a way to regulate that molecule's activity for
                            therapeutic purposes.
                          • target validation - a crucial step in the drug
                            development process. Following the identification of a
                            potential disease target, target validation verifies that a
                            drug that specifically acts on the target can have a
                            significant therapeutic benefit in the treatment of a given
                            disease.
Functional Genomics ?


               More than running chip experiments !
                               Phenotypic Gap
                                                 Total # genes

                                                 Proposal to prioritize
                                                    hypothetical protein
 Number of genes                                    without annotation, nice
                                                    for bioinformatics and
                                                    biologist

                                                 # genes with
                                                 known function


                        1980     1990   2000   2010
Where is optimal drug target ?
     “Optimal” drug target
     Predict side effect
How to correct disease state



Side effects ?
Genome-wide RNAi




                                                          RNAI vector



                                                      proprietary nematode
20.000 genes insert   bacteria producing ds RNA for
                                                       responding to RNAi
      library           each of the 20.000 genes
                                                        20.000 responses
Type-II Diabetes

Normal insulin signaling




                fat storage LOW

Reduced insulin signaling




                fat storage HIGH
Industrialized knock-downs
                      proprietary C.elegans strains
                      • sensitized to silencing
                      • sensitized to relevant pathway



20,000 bacteria
each containing
selected
C. elegans gene



                  select genes with desired phenotypes
Pharma is conservative
Structural Genomics
               Molecular functions of 26 383 human genes
Lipinsky for the target ?



   Database of all “drugable” human genes
Drug Discovery: Design new drugs by computer?
Drug Discovery: Screening definitions

                          screening - the automated examination and
                          testing of libraries of synthetic and/or organic
                          compounds and extracts to identify potential drug
                          leads, based on the compound's binding affinity
                          for a target molecule.
                          screening library - a large collection of
                          compounds with different chemical properties or
                          shapes, generated either by combinatorial
                          chemistry or some other process or by collecting
                          samples with interesting biological properties.
                          High Throughput Screening: Quick and Dirty…
                          from 5000 compounds per day
Drug Discovery: Screening Throughput

                         • At the beginning of the 1990s, when the
                           term "high-throughput screening" was
                           coined, a department of 20 would
                           typically be able to screen around 1.5
                           million samples in a year, each
                           researcher handling around 75,000
                           samples. Today, four researchers using
                           fully automated robotic technology can
                           screen 50,000 samples a day, or around
                           2.5 million samples each year.
Drug Discovery: HTS – The Wet Lab




      Distribution
      96 / 384 wells




    Read-out
  Fluorescence /
  luminescence




                                    Robotic arm
 Optical Bank
  for stability
Drug Discovery: Chemistry Sources


                         • Available molecules collections from pharma,
                           chemical and agro industry, also from
                           academics (Eastern Europe)
                         • Natural products from fungi, algae, exotic
                           plants, Chinese and ethnobotanic medicines
                         • Combinatorial chemistry: it is the generation
                           of large numbers of diverse chemical
                           compounds (a library) for use in screening
                           assays against disease target molecules.
                         • Computer drug design (from model
                           substrates or X-ray structure)
Drug Discovery




         HIT     LEAD
Drug Discovery: HIT


                      • initial screen established
                      • Compounds screened
                      • IC50s established
                      • Structures verified
                      • Minimum of threeindependent
                         chemicalseries to evaluate
                      • Positive in silico PKdata
Drug Discovery: Hit/lead computational approaches


    • When the structure of the target is unknown,
      the activity data can be used to construct a
      pharmacophore model for the positioning of
      key features like hydrogen-bonding and
      hydrophobic groups.
    • Such a model can be used as a template to
      select the most promising candidates from the
      library.
Drug Discovery: Lead ?

                         •   lead compound - a potential drug candidate emerging from a
                             screening process of a large library of compounds.
                         •   It basically affects specifically a biological process.
                             Mechanism of activity (reversible/irreversible,kinetics)
                             established
                         •   Its is effective at a low concentration: usually nanomolar
                             activity
                         •   It is not toxic to live cells
                         •   It has been shown to have some in vivo activity
                         •   It is chemically feasible. Specificity of keycompound(s)
                             fromeach leadseriesagainst selectednumber
                             ofreceptors/enzymes
                         •   Preliminary PK in vivo(rodent) to establishbenchmark for in
                             vitroSAR
                         •   In vitro PK data goodpredictor for in vivoactivity
                         •   Its is of course New and Original.
Lipinski: « rule of 5 »


"In the USAN set we found that the sum of Ns and Os in the molecular formula was
     greater than 10 in 12% of the compounds. Eleven percent of compounds had
     a MWT of over 500. Ten percent of compounds had a CLogP larger than 5 (or
     an MLogP larger than 4.15) and in 8% of compounds the sum of OHs and NHs
     in the chemical structure was larger than 5. The "rule of 5" states that: poor
     absorption or permeation is more likely when:
A. There are less than 5 H-bond donors (expressed as the sum of OHs and
     NHs);
B. The MWT is less than 500;
C. The LogP is less than 5 (or MLogP is < 4.15);
D. There are less than 10 H-bond acceptors (expressed as the sum of Ns and
     Os).
Compound classes that are substrates for biological transporters are exceptions to
     the rule."

Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy, Paul J. Feeney
"Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings":
• A quick sketch with ChemDraw, conversion to a
  3D structure with Chem3D, and processing by
  QuikProp, reveals that the problem appears to be
  poor cell permeability for this relatively polar
  molecule, with predicted PCaco and PMDCK
  values near 10 nm/s.
• Free alternative (Chemsketch / PreADME)
(Celebrex)
Methyl in this position makes it a weaker cox-2 inhibitor,

but site of metabolic oxidation and ensures an acceptable clearance




                  Drug-like-ness
To assist combinatorial chemistry, buy specific compunds
Structural Descriptors: (15 descriptors)
Molecular Formula, Molecular Weight, Formal Charge, The Number of Rotatable Bonds, The Number of Rigid
     Bonds, The Number of Rings, The Number of Aromatic Rings, The Number of H Bond Acceptors, The
     Number of H Bond Donors, The Number of (+) Charged Groups, The Number of (-) Charged Groups, No.
     single, double, triple, aromatic bonds

Topological Descriptors:(350 descriptors)
•   Topological descriptors on the adjustancy and distance matrix
•   Count descriptors
•   Kier & Hall molecular connectivity Indices
•   Kier Shape Indices
•   Galvez topological charge Indices
•   Narumi topological index
•   Autocorrelation descriptor of atomic masses, atomic polarizability, Pauling electronegativity and van der
    Waals radius
•   Information content descriptors
•   Electrotopological state index (E-state)
•   Atomic-Level-Based AI topological descriptors

Physicochemical Descriptor:(10 descriptors)
AlogP98 (calculated logP), SKlogP (calculated logP), SKlogS in pure water (calculated water solubility), SKlogS in
    buffer system (calculated water solubility),SK vap (calculated vapor pressure), SK bp (calculated boiling
    point), SK mp (calculated meling point), AMR (calculated molecular refractivity), APOL(calculated
    polarizability), Water Solvation Free Energy

Geometrical Descriptor:(9 descriptors)
Topological Polar Surface Area, 2D van der Waals Volume, 2D van der Waals Surface Area, 2D van der Waals
    Hydrophobic Surface Area, 2D van der Waals Polar Surface Area, 2D van der Waals H-bond Acceptor Surface
    Area, 2D van der Waals H-bond Donor Surface Area, 2D van der Waals (+) Charged Groups Surface Area, 2D
    van der Waals (-) Charged Groups Surface Area
Drug Discovery: Hit/lead computational approaches



   • What can you do with these descriptors ?

   • Cluster entire chemical library
        – Diversity set
        – Focused set
Drug Discovery: Docking

    • Structure is known, virtual screening -> docking
    • Many different approaches
         –   DOCK
         –   FlexX
         –   Glide
         –   GOLD
    • Including conformational sampling of the ligand
    • Problem:
         – host flexibility
         – solvatation
    • Example: Bissantz et al.
         – Hit rate of 10% for single scoring function
         – Up to 70% with triple scoring (bagging)
Drug Discovery: De novo design / rational drug design




                                       • Given the target site:
                                       • Docking + structure generator
                                       • Specialized approach: growing
                                         substituent on a core
                                            – LUDI
                                            – SPROUT
                                            – BOMB (biochemical and organic model
                                              builder)
                                            – SYNOPSIS
                                       • Problem is the scoring function
                                         which is different for every protein
                                         class
Drug Discovery: Novel strategies using bio/cheminformatics


   - HTS ? Chemical space is big (1041)
   - Biased sets/focussed libraries ->bioinformatics !!!
   - How ? Use phylogenetics and known structures to define
   accesible (conserved) functional implicated residues to
   define small molecule pharmacophores (minimal
   requirements)
   - Desciptor search (cheminformatics) to construct/select
   biased compound set
   - ensure serendipity by iterative screening of these
   predesigned sets
Drug Discovery




                   Toxigenomics
                 Metabogenomics
Drug Discovery: Clinical studies

                           • Preclinical - An early phase of development
                             including initial safety assessment
                             Phase I - Evaluation of clinical pharmacology,
                             usually conducted in volunteers
                             Phase II - Determination of dose and initial
                             evaluation of efficacy, conducted in a small
                             number of patients
                             Phase III - Large comparative study
                             (compound versus placebo and/or established
                             treatment) in patients to establish clinical
                             benefit and safety
                             Phase IV - Post marketing study
Drug Discovery & Development: IND filing
Hapmap
Pharmacogenomics




                   Predictive/preventive – systems biology
Sneak preview
Bioinformatics (re)loaded
Sneak preview
       Bioinformatics (re)loaded
• Relational datamodels
  – BioSQL (MySQL)
• Data Visualisation
  – Interface
     • Apache
     • PHP
• Large Scale Statistics
  – Using R

More Related Content

What's hot

Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the ...
Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the ...Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the ...
Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the ...Rajarshi Guha
 
Session 2 part 1
Session 2 part 1Session 2 part 1
Session 2 part 1plmiami
 
Friend UCSF 2012-07-27
Friend UCSF 2012-07-27Friend UCSF 2012-07-27
Friend UCSF 2012-07-27Sage Base
 
Drug discovery process style 5 powerpoint presentation slides db ppt templates
Drug discovery process style 5 powerpoint presentation slides db ppt templatesDrug discovery process style 5 powerpoint presentation slides db ppt templates
Drug discovery process style 5 powerpoint presentation slides db ppt templatesSlideTeam.net
 
Stephen Friend AMIA Symposium 2012-03-21
Stephen Friend AMIA Symposium 2012-03-21Stephen Friend AMIA Symposium 2012-03-21
Stephen Friend AMIA Symposium 2012-03-21Sage Base
 
BRAINco Biopharma company presentation
BRAINco Biopharma company presentationBRAINco Biopharma company presentation
BRAINco Biopharma company presentationbraincosm
 
Cell based assays presentation V2_03_2012
Cell based assays presentation V2_03_2012Cell based assays presentation V2_03_2012
Cell based assays presentation V2_03_2012Pete Shuster
 
20120615_Granatum_COST_v2
20120615_Granatum_COST_v220120615_Granatum_COST_v2
20120615_Granatum_COST_v2Christos Kannas
 
Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...SlideTeam.net
 
Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...SlideTeam.net
 
The Life Science Product Manager's Toolkit
The Life Science Product Manager's ToolkitThe Life Science Product Manager's Toolkit
The Life Science Product Manager's Toolkitprothenberg
 
Target selection lead discovery medicinal drug discovery process style design...
Target selection lead discovery medicinal drug discovery process style design...Target selection lead discovery medicinal drug discovery process style design...
Target selection lead discovery medicinal drug discovery process style design...SlideTeam.net
 
Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...SlideTeam.net
 
Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...SlideTeam.net
 
Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...SlideTeam.net
 
Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...SlideTeam.net
 
Target selection lead discovery medicinal drug discovery strategy design 5 po...
Target selection lead discovery medicinal drug discovery strategy design 5 po...Target selection lead discovery medicinal drug discovery strategy design 5 po...
Target selection lead discovery medicinal drug discovery strategy design 5 po...SlideTeam.net
 
Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...SlideTeam.net
 
Target selection lead discovery medicinal drug discovery process style design...
Target selection lead discovery medicinal drug discovery process style design...Target selection lead discovery medicinal drug discovery process style design...
Target selection lead discovery medicinal drug discovery process style design...SlideTeam.net
 

What's hot (20)

Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the ...
Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the ...Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the ...
Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the ...
 
Session 2 part 1
Session 2 part 1Session 2 part 1
Session 2 part 1
 
Friend UCSF 2012-07-27
Friend UCSF 2012-07-27Friend UCSF 2012-07-27
Friend UCSF 2012-07-27
 
Evaluation of antibody drugs quality safety
Evaluation of antibody drugs quality safetyEvaluation of antibody drugs quality safety
Evaluation of antibody drugs quality safety
 
Drug discovery process style 5 powerpoint presentation slides db ppt templates
Drug discovery process style 5 powerpoint presentation slides db ppt templatesDrug discovery process style 5 powerpoint presentation slides db ppt templates
Drug discovery process style 5 powerpoint presentation slides db ppt templates
 
Stephen Friend AMIA Symposium 2012-03-21
Stephen Friend AMIA Symposium 2012-03-21Stephen Friend AMIA Symposium 2012-03-21
Stephen Friend AMIA Symposium 2012-03-21
 
BRAINco Biopharma company presentation
BRAINco Biopharma company presentationBRAINco Biopharma company presentation
BRAINco Biopharma company presentation
 
Cell based assays presentation V2_03_2012
Cell based assays presentation V2_03_2012Cell based assays presentation V2_03_2012
Cell based assays presentation V2_03_2012
 
20120615_Granatum_COST_v2
20120615_Granatum_COST_v220120615_Granatum_COST_v2
20120615_Granatum_COST_v2
 
Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...
 
Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...
 
The Life Science Product Manager's Toolkit
The Life Science Product Manager's ToolkitThe Life Science Product Manager's Toolkit
The Life Science Product Manager's Toolkit
 
Target selection lead discovery medicinal drug discovery process style design...
Target selection lead discovery medicinal drug discovery process style design...Target selection lead discovery medicinal drug discovery process style design...
Target selection lead discovery medicinal drug discovery process style design...
 
Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...
 
Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...
 
Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...
 
Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...Target selection lead discovery medicinal drug discovery strategy style desig...
Target selection lead discovery medicinal drug discovery strategy style desig...
 
Target selection lead discovery medicinal drug discovery strategy design 5 po...
Target selection lead discovery medicinal drug discovery strategy design 5 po...Target selection lead discovery medicinal drug discovery strategy design 5 po...
Target selection lead discovery medicinal drug discovery strategy design 5 po...
 
Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...Target selection lead discovery medicinal drug discovery process design 5 pow...
Target selection lead discovery medicinal drug discovery process design 5 pow...
 
Target selection lead discovery medicinal drug discovery process style design...
Target selection lead discovery medicinal drug discovery process style design...Target selection lead discovery medicinal drug discovery process style design...
Target selection lead discovery medicinal drug discovery process style design...
 

Viewers also liked

2014 05 21_personal_genomics_v_n2n_vfinal
2014 05 21_personal_genomics_v_n2n_vfinal2014 05 21_personal_genomics_v_n2n_vfinal
2014 05 21_personal_genomics_v_n2n_vfinalProf. Wim Van Criekinge
 
Bio ontologies and semantic technologies
Bio ontologies and semantic technologiesBio ontologies and semantic technologies
Bio ontologies and semantic technologiesProf. Wim Van Criekinge
 
2012 12 02_epigenetic_profiling_environmental_health_sciences
2012 12 02_epigenetic_profiling_environmental_health_sciences2012 12 02_epigenetic_profiling_environmental_health_sciences
2012 12 02_epigenetic_profiling_environmental_health_sciencesProf. Wim Van Criekinge
 
Van criekinge next_generation_epigenetic_profling_vlille
Van criekinge next_generation_epigenetic_profling_vlilleVan criekinge next_generation_epigenetic_profling_vlille
Van criekinge next_generation_epigenetic_profling_vlilleProf. Wim Van Criekinge
 
2015 bioinformatics alignments_wim_vancriekinge
2015 bioinformatics alignments_wim_vancriekinge2015 bioinformatics alignments_wim_vancriekinge
2015 bioinformatics alignments_wim_vancriekingeProf. Wim Van Criekinge
 
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vwebProf. Wim Van Criekinge
 
Bioinformatics t7-proteinstructure v2014
Bioinformatics t7-proteinstructure v2014Bioinformatics t7-proteinstructure v2014
Bioinformatics t7-proteinstructure v2014Prof. Wim Van Criekinge
 
2015 09 imec_wim_vancriekinge_v42_to_present
2015 09 imec_wim_vancriekinge_v42_to_present2015 09 imec_wim_vancriekinge_v42_to_present
2015 09 imec_wim_vancriekinge_v42_to_presentProf. Wim Van Criekinge
 
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitterProf. Wim Van Criekinge
 
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013Prof. Wim Van Criekinge
 

Viewers also liked (20)

2014 05 21_personal_genomics_v_n2n_vfinal
2014 05 21_personal_genomics_v_n2n_vfinal2014 05 21_personal_genomics_v_n2n_vfinal
2014 05 21_personal_genomics_v_n2n_vfinal
 
Bio ontologies and semantic technologies
Bio ontologies and semantic technologiesBio ontologies and semantic technologies
Bio ontologies and semantic technologies
 
Bioinformatica 27-10-2011-t4-alignments
Bioinformatica 27-10-2011-t4-alignmentsBioinformatica 27-10-2011-t4-alignments
Bioinformatica 27-10-2011-t4-alignments
 
Mini symposium
Mini symposiumMini symposium
Mini symposium
 
2012 12 02_epigenetic_profiling_environmental_health_sciences
2012 12 02_epigenetic_profiling_environmental_health_sciences2012 12 02_epigenetic_profiling_environmental_health_sciences
2012 12 02_epigenetic_profiling_environmental_health_sciences
 
Bioinformatica t3-scoring matrices
Bioinformatica t3-scoring matricesBioinformatica t3-scoring matrices
Bioinformatica t3-scoring matrices
 
Bioinformatica p1-perl-introduction
Bioinformatica p1-perl-introductionBioinformatica p1-perl-introduction
Bioinformatica p1-perl-introduction
 
Van criekinge next_generation_epigenetic_profling_vlille
Van criekinge next_generation_epigenetic_profling_vlilleVan criekinge next_generation_epigenetic_profling_vlille
Van criekinge next_generation_epigenetic_profling_vlille
 
2015 bioinformatics bio_python_part4
2015 bioinformatics bio_python_part42015 bioinformatics bio_python_part4
2015 bioinformatics bio_python_part4
 
Bioinformatics v2014 wim_vancriekinge
Bioinformatics v2014 wim_vancriekingeBioinformatics v2014 wim_vancriekinge
Bioinformatics v2014 wim_vancriekinge
 
2015 bioinformatics alignments_wim_vancriekinge
2015 bioinformatics alignments_wim_vancriekinge2015 bioinformatics alignments_wim_vancriekinge
2015 bioinformatics alignments_wim_vancriekinge
 
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
 
2015 bioinformatics bio_python_partii
2015 bioinformatics bio_python_partii2015 bioinformatics bio_python_partii
2015 bioinformatics bio_python_partii
 
Bioinformatics t7-proteinstructure v2014
Bioinformatics t7-proteinstructure v2014Bioinformatics t7-proteinstructure v2014
Bioinformatics t7-proteinstructure v2014
 
Bioinformatica t7-protein structure
Bioinformatica t7-protein structureBioinformatica t7-protein structure
Bioinformatica t7-protein structure
 
2015 bioinformatics bio_python_part3
2015 bioinformatics bio_python_part32015 bioinformatics bio_python_part3
2015 bioinformatics bio_python_part3
 
2015 09 imec_wim_vancriekinge_v42_to_present
2015 09 imec_wim_vancriekinge_v42_to_present2015 09 imec_wim_vancriekinge_v42_to_present
2015 09 imec_wim_vancriekinge_v42_to_present
 
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
 
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
 
Bioinformatics life sciences_2012
Bioinformatics life sciences_2012Bioinformatics life sciences_2012
Bioinformatics life sciences_2012
 

Similar to Bioinformatica t9-t10-biocheminformatics

Bioinformatics t9-t10-biocheminformatics v2014
Bioinformatics t9-t10-biocheminformatics v2014Bioinformatics t9-t10-biocheminformatics v2014
Bioinformatics t9-t10-biocheminformatics v2014Prof. Wim Van Criekinge
 
Friend NAS 2013-01-10
Friend NAS 2013-01-10Friend NAS 2013-01-10
Friend NAS 2013-01-10Sage Base
 
Lecture 8 drug targets and target identification
Lecture 8 drug targets and target identificationLecture 8 drug targets and target identification
Lecture 8 drug targets and target identificationRAJAN ROLTA
 
Genomics In Personal Care Product Development
Genomics In Personal Care Product DevelopmentGenomics In Personal Care Product Development
Genomics In Personal Care Product DevelopmentGenemarkers
 
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...OECD Environment
 
Bioinformatica 15-12-2011-t9-t10-bio cheminformatics
Bioinformatica 15-12-2011-t9-t10-bio cheminformaticsBioinformatica 15-12-2011-t9-t10-bio cheminformatics
Bioinformatica 15-12-2011-t9-t10-bio cheminformaticsProf. Wim Van Criekinge
 
2015 bioinformatics bio_cheminformatics_wim_vancriekinge
2015 bioinformatics bio_cheminformatics_wim_vancriekinge2015 bioinformatics bio_cheminformatics_wim_vancriekinge
2015 bioinformatics bio_cheminformatics_wim_vancriekingeProf. Wim Van Criekinge
 
Drug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsDrug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsKedar Bandekar
 
Drug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsDrug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsKedar Bandekar
 
2016 bioinformatics i_bio_cheminformatics_wimvancriekinge
2016 bioinformatics i_bio_cheminformatics_wimvancriekinge2016 bioinformatics i_bio_cheminformatics_wimvancriekinge
2016 bioinformatics i_bio_cheminformatics_wimvancriekingeProf. Wim Van Criekinge
 
Towards Systems Pharmacology
Towards Systems PharmacologyTowards Systems Pharmacology
Towards Systems PharmacologyPhilip Bourne
 
Natural products in drug discovery
Natural products in drug discoveryNatural products in drug discovery
Natural products in drug discoverySAKTHIVEL G
 
Session 4 part 1
Session 4 part 1Session 4 part 1
Session 4 part 1plmiami
 
Role of Bioinformatics in Plant Pathology.pptx
Role of Bioinformatics in Plant Pathology.pptxRole of Bioinformatics in Plant Pathology.pptx
Role of Bioinformatics in Plant Pathology.pptxHasanRiaz18
 
Recombinant Dna technology, Restriction Endonucleas and Vector
Recombinant Dna technology, Restriction Endonucleas and Vector Recombinant Dna technology, Restriction Endonucleas and Vector
Recombinant Dna technology, Restriction Endonucleas and Vector Dr. Priti D. Diwan
 
Friend NRNB 2012-12-13
Friend NRNB 2012-12-13Friend NRNB 2012-12-13
Friend NRNB 2012-12-13Sage Base
 
The Translational Medicine
The Translational MedicineThe Translational Medicine
The Translational MedicineJoanne Luciano
 
GENOMICS AND BIOINFORMATICS
GENOMICS AND BIOINFORMATICSGENOMICS AND BIOINFORMATICS
GENOMICS AND BIOINFORMATICSsandeshGM
 

Similar to Bioinformatica t9-t10-biocheminformatics (20)

Bioinformatics t9-t10-biocheminformatics v2014
Bioinformatics t9-t10-biocheminformatics v2014Bioinformatics t9-t10-biocheminformatics v2014
Bioinformatics t9-t10-biocheminformatics v2014
 
Friend NAS 2013-01-10
Friend NAS 2013-01-10Friend NAS 2013-01-10
Friend NAS 2013-01-10
 
Lecture 8 drug targets and target identification
Lecture 8 drug targets and target identificationLecture 8 drug targets and target identification
Lecture 8 drug targets and target identification
 
Genomics In Personal Care Product Development
Genomics In Personal Care Product DevelopmentGenomics In Personal Care Product Development
Genomics In Personal Care Product Development
 
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...
 
Bioinformatica 15-12-2011-t9-t10-bio cheminformatics
Bioinformatica 15-12-2011-t9-t10-bio cheminformaticsBioinformatica 15-12-2011-t9-t10-bio cheminformatics
Bioinformatica 15-12-2011-t9-t10-bio cheminformatics
 
2015 bioinformatics bio_cheminformatics_wim_vancriekinge
2015 bioinformatics bio_cheminformatics_wim_vancriekinge2015 bioinformatics bio_cheminformatics_wim_vancriekinge
2015 bioinformatics bio_cheminformatics_wim_vancriekinge
 
Drug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsDrug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugs
 
Drug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsDrug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugs
 
2016 bioinformatics i_bio_cheminformatics_wimvancriekinge
2016 bioinformatics i_bio_cheminformatics_wimvancriekinge2016 bioinformatics i_bio_cheminformatics_wimvancriekinge
2016 bioinformatics i_bio_cheminformatics_wimvancriekinge
 
Molecular profiling 2012
Molecular profiling 2012Molecular profiling 2012
Molecular profiling 2012
 
Bioinformatics
BioinformaticsBioinformatics
Bioinformatics
 
Towards Systems Pharmacology
Towards Systems PharmacologyTowards Systems Pharmacology
Towards Systems Pharmacology
 
Natural products in drug discovery
Natural products in drug discoveryNatural products in drug discovery
Natural products in drug discovery
 
Session 4 part 1
Session 4 part 1Session 4 part 1
Session 4 part 1
 
Role of Bioinformatics in Plant Pathology.pptx
Role of Bioinformatics in Plant Pathology.pptxRole of Bioinformatics in Plant Pathology.pptx
Role of Bioinformatics in Plant Pathology.pptx
 
Recombinant Dna technology, Restriction Endonucleas and Vector
Recombinant Dna technology, Restriction Endonucleas and Vector Recombinant Dna technology, Restriction Endonucleas and Vector
Recombinant Dna technology, Restriction Endonucleas and Vector
 
Friend NRNB 2012-12-13
Friend NRNB 2012-12-13Friend NRNB 2012-12-13
Friend NRNB 2012-12-13
 
The Translational Medicine
The Translational MedicineThe Translational Medicine
The Translational Medicine
 
GENOMICS AND BIOINFORMATICS
GENOMICS AND BIOINFORMATICSGENOMICS AND BIOINFORMATICS
GENOMICS AND BIOINFORMATICS
 

More from Prof. Wim Van Criekinge

2019 03 05_biological_databases_part5_v_upload
2019 03 05_biological_databases_part5_v_upload2019 03 05_biological_databases_part5_v_upload
2019 03 05_biological_databases_part5_v_uploadProf. Wim Van Criekinge
 
2019 03 05_biological_databases_part4_v_upload
2019 03 05_biological_databases_part4_v_upload2019 03 05_biological_databases_part4_v_upload
2019 03 05_biological_databases_part4_v_uploadProf. Wim Van Criekinge
 
2019 03 05_biological_databases_part3_v_upload
2019 03 05_biological_databases_part3_v_upload2019 03 05_biological_databases_part3_v_upload
2019 03 05_biological_databases_part3_v_uploadProf. Wim Van Criekinge
 
2019 02 21_biological_databases_part2_v_upload
2019 02 21_biological_databases_part2_v_upload2019 02 21_biological_databases_part2_v_upload
2019 02 21_biological_databases_part2_v_uploadProf. Wim Van Criekinge
 
2019 02 12_biological_databases_part1_v_upload
2019 02 12_biological_databases_part1_v_upload2019 02 12_biological_databases_part1_v_upload
2019 02 12_biological_databases_part1_v_uploadProf. Wim Van Criekinge
 
Bio ontologies and semantic technologies[2]
Bio ontologies and semantic technologies[2]Bio ontologies and semantic technologies[2]
Bio ontologies and semantic technologies[2]Prof. Wim Van Criekinge
 
2018 03 27_biological_databases_part4_v_upload
2018 03 27_biological_databases_part4_v_upload2018 03 27_biological_databases_part4_v_upload
2018 03 27_biological_databases_part4_v_uploadProf. Wim Van Criekinge
 
2018 02 20_biological_databases_part2_v_upload
2018 02 20_biological_databases_part2_v_upload2018 02 20_biological_databases_part2_v_upload
2018 02 20_biological_databases_part2_v_uploadProf. Wim Van Criekinge
 
2018 02 20_biological_databases_part1_v_upload
2018 02 20_biological_databases_part1_v_upload2018 02 20_biological_databases_part1_v_upload
2018 02 20_biological_databases_part1_v_uploadProf. Wim Van Criekinge
 

More from Prof. Wim Van Criekinge (20)

2020 02 11_biological_databases_part1
2020 02 11_biological_databases_part12020 02 11_biological_databases_part1
2020 02 11_biological_databases_part1
 
2019 03 05_biological_databases_part5_v_upload
2019 03 05_biological_databases_part5_v_upload2019 03 05_biological_databases_part5_v_upload
2019 03 05_biological_databases_part5_v_upload
 
2019 03 05_biological_databases_part4_v_upload
2019 03 05_biological_databases_part4_v_upload2019 03 05_biological_databases_part4_v_upload
2019 03 05_biological_databases_part4_v_upload
 
2019 03 05_biological_databases_part3_v_upload
2019 03 05_biological_databases_part3_v_upload2019 03 05_biological_databases_part3_v_upload
2019 03 05_biological_databases_part3_v_upload
 
2019 02 21_biological_databases_part2_v_upload
2019 02 21_biological_databases_part2_v_upload2019 02 21_biological_databases_part2_v_upload
2019 02 21_biological_databases_part2_v_upload
 
2019 02 12_biological_databases_part1_v_upload
2019 02 12_biological_databases_part1_v_upload2019 02 12_biological_databases_part1_v_upload
2019 02 12_biological_databases_part1_v_upload
 
P7 2018 biopython3
P7 2018 biopython3P7 2018 biopython3
P7 2018 biopython3
 
P6 2018 biopython2b
P6 2018 biopython2bP6 2018 biopython2b
P6 2018 biopython2b
 
P4 2018 io_functions
P4 2018 io_functionsP4 2018 io_functions
P4 2018 io_functions
 
P3 2018 python_regexes
P3 2018 python_regexesP3 2018 python_regexes
P3 2018 python_regexes
 
T1 2018 bioinformatics
T1 2018 bioinformaticsT1 2018 bioinformatics
T1 2018 bioinformatics
 
P1 2018 python
P1 2018 pythonP1 2018 python
P1 2018 python
 
Bio ontologies and semantic technologies[2]
Bio ontologies and semantic technologies[2]Bio ontologies and semantic technologies[2]
Bio ontologies and semantic technologies[2]
 
2018 05 08_biological_databases_no_sql
2018 05 08_biological_databases_no_sql2018 05 08_biological_databases_no_sql
2018 05 08_biological_databases_no_sql
 
2018 03 27_biological_databases_part4_v_upload
2018 03 27_biological_databases_part4_v_upload2018 03 27_biological_databases_part4_v_upload
2018 03 27_biological_databases_part4_v_upload
 
2018 03 20_biological_databases_part3
2018 03 20_biological_databases_part32018 03 20_biological_databases_part3
2018 03 20_biological_databases_part3
 
2018 02 20_biological_databases_part2_v_upload
2018 02 20_biological_databases_part2_v_upload2018 02 20_biological_databases_part2_v_upload
2018 02 20_biological_databases_part2_v_upload
 
2018 02 20_biological_databases_part1_v_upload
2018 02 20_biological_databases_part1_v_upload2018 02 20_biological_databases_part1_v_upload
2018 02 20_biological_databases_part1_v_upload
 
P7 2017 biopython3
P7 2017 biopython3P7 2017 biopython3
P7 2017 biopython3
 
P6 2017 biopython2
P6 2017 biopython2P6 2017 biopython2
P6 2017 biopython2
 

Recently uploaded

Culture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxCulture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxPoojaSen20
 
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfAMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfphamnguyenenglishnb
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Jisc
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4MiaBumagat1
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfSpandanaRallapalli
 
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYKayeClaireEstoconing
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 
Judging the Relevance and worth of ideas part 2.pptx
Judging the Relevance  and worth of ideas part 2.pptxJudging the Relevance  and worth of ideas part 2.pptx
Judging the Relevance and worth of ideas part 2.pptxSherlyMaeNeri
 
Choosing the Right CBSE School A Comprehensive Guide for Parents
Choosing the Right CBSE School A Comprehensive Guide for ParentsChoosing the Right CBSE School A Comprehensive Guide for Parents
Choosing the Right CBSE School A Comprehensive Guide for Parentsnavabharathschool99
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptxmary850239
 
Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Seán Kennedy
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...Postal Advocate Inc.
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomnelietumpap1
 
Karra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxKarra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxAshokKarra1
 
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...Nguyen Thanh Tu Collection
 
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfVirtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfErwinPantujan2
 

Recently uploaded (20)

Culture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxCulture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptx
 
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfAMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdf
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 
Judging the Relevance and worth of ideas part 2.pptx
Judging the Relevance  and worth of ideas part 2.pptxJudging the Relevance  and worth of ideas part 2.pptx
Judging the Relevance and worth of ideas part 2.pptx
 
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptxYOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
 
Choosing the Right CBSE School A Comprehensive Guide for Parents
Choosing the Right CBSE School A Comprehensive Guide for ParentsChoosing the Right CBSE School A Comprehensive Guide for Parents
Choosing the Right CBSE School A Comprehensive Guide for Parents
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx
 
Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choom
 
Karra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxKarra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptx
 
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
 
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfVirtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
 

Bioinformatica t9-t10-biocheminformatics

  • 1.
  • 2. FBW 11-12-2012 Wim Van Criekinge
  • 5. Examen <html> <title>Examen Bioinformatica</title> <center> <head> <script> rnd.today=new Date(); rnd.seed=rnd.today.getTime(); function rnd() { rnd.seed = (rnd.seed*9301+49297) % 233280; return rnd.seed/(233280.0); }; function rand(number) { return Math.ceil(rnd()*number); }; </SCRIPT> </head> <body bgcolor="#FFFFFF" text="#00FF00" link="#00FF00"> <script language="JavaScript"> document.write('<table>'); document.write('<tr>'); document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" height="360"></a></td>'); rand(98); document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" height="360"></a></td>'); rand(98); document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" height="360"></a></td>'); rand(98); document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" height="360"></a></td>'); rand(98);
  • 6. Comparative Genomics: The biological Rosetta • The keywords can be – genome structure – gene-organisation – known promoter regions – known critical amino acid residues. • Combination of functional modelorganism knowledge • Structure-function • Identify similar areas of biology • Identify orthologous pathways (might have different endpoints)
  • 7.
  • 8. Example: Agro Sequence Genome Known “lethal” genes from worm, drosphila Filter for drugability”, tractibility & novelty
  • 9. Example: Extremophiles Look for species Sequence Genome with interesting phenotypes Functional Foods Convert Highly Energetic Monosaccharides to Dextrane Washing Powder additives Known lipases Filter for “workable”lipases at 90º C Clone and produce in large quantities
  • 10.
  • 11. Drug Discovery: Design new drugs by computer? Problem: pipeline cost rise linear, NCE steady Money: bypassing difficult, work on attrition Every step requires specific computational tools
  • 12. Drug Discovery: What is a drug ? • Drugs are generally defined as molecules which affect biological processes. • In order to be effective, the molecule must be present in the body at an adequate concentration for it to act at the specific site in the body where it can exert its effect. • Additionally, the molecule must be safe -- that is, metabolized and eliminated from the body without causing injury. • Assumption: next 50 years still a big market in small chemical entities which can be administered orally in form of a pill (in contrast to antibodies) or gene therapy …
  • 13.
  • 14.
  • 15.
  • 16.
  • 17. • Taxol a drug which is an unmodified natural compound, is the exception • Most drugs require “work” -> need for target driven pipeline • Humane genome is available so all target are identified • How to validate (within a given disease area) ?
  • 18. Drug Discovery: What is a target ? • target - a molecule (often a protein) that is instrumental to a disease process (though not necessarily directly involved), which may be targeted with a potential therapeutic. • target identification - identifying a molecule (often a protein) that is instrumental to a disease process (though not necessarily directly involved), with the intention of finding a way to regulate that molecule's activity for therapeutic purposes. • target validation - a crucial step in the drug development process. Following the identification of a potential disease target, target validation verifies that a drug that specifically acts on the target can have a significant therapeutic benefit in the treatment of a given disease.
  • 19. Functional Genomics ? More than running chip experiments ! Phenotypic Gap Total # genes Proposal to prioritize hypothetical protein Number of genes without annotation, nice for bioinformatics and biologist # genes with known function 1980 1990 2000 2010
  • 20.
  • 21. Where is optimal drug target ? “Optimal” drug target Predict side effect How to correct disease state Side effects ?
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28. Genome-wide RNAi RNAI vector proprietary nematode 20.000 genes insert bacteria producing ds RNA for responding to RNAi library each of the 20.000 genes 20.000 responses
  • 29.
  • 30.
  • 31. Type-II Diabetes Normal insulin signaling fat storage LOW Reduced insulin signaling fat storage HIGH
  • 32. Industrialized knock-downs proprietary C.elegans strains • sensitized to silencing • sensitized to relevant pathway 20,000 bacteria each containing selected C. elegans gene select genes with desired phenotypes
  • 34.
  • 35. Structural Genomics Molecular functions of 26 383 human genes
  • 36.
  • 37. Lipinsky for the target ? Database of all “drugable” human genes
  • 38. Drug Discovery: Design new drugs by computer?
  • 39. Drug Discovery: Screening definitions screening - the automated examination and testing of libraries of synthetic and/or organic compounds and extracts to identify potential drug leads, based on the compound's binding affinity for a target molecule. screening library - a large collection of compounds with different chemical properties or shapes, generated either by combinatorial chemistry or some other process or by collecting samples with interesting biological properties. High Throughput Screening: Quick and Dirty… from 5000 compounds per day
  • 40. Drug Discovery: Screening Throughput • At the beginning of the 1990s, when the term "high-throughput screening" was coined, a department of 20 would typically be able to screen around 1.5 million samples in a year, each researcher handling around 75,000 samples. Today, four researchers using fully automated robotic technology can screen 50,000 samples a day, or around 2.5 million samples each year.
  • 41. Drug Discovery: HTS – The Wet Lab Distribution 96 / 384 wells Read-out Fluorescence / luminescence Robotic arm Optical Bank for stability
  • 42. Drug Discovery: Chemistry Sources • Available molecules collections from pharma, chemical and agro industry, also from academics (Eastern Europe) • Natural products from fungi, algae, exotic plants, Chinese and ethnobotanic medicines • Combinatorial chemistry: it is the generation of large numbers of diverse chemical compounds (a library) for use in screening assays against disease target molecules. • Computer drug design (from model substrates or X-ray structure)
  • 43. Drug Discovery HIT LEAD
  • 44. Drug Discovery: HIT • initial screen established • Compounds screened • IC50s established • Structures verified • Minimum of threeindependent chemicalseries to evaluate • Positive in silico PKdata
  • 45. Drug Discovery: Hit/lead computational approaches • When the structure of the target is unknown, the activity data can be used to construct a pharmacophore model for the positioning of key features like hydrogen-bonding and hydrophobic groups. • Such a model can be used as a template to select the most promising candidates from the library.
  • 46. Drug Discovery: Lead ? • lead compound - a potential drug candidate emerging from a screening process of a large library of compounds. • It basically affects specifically a biological process. Mechanism of activity (reversible/irreversible,kinetics) established • Its is effective at a low concentration: usually nanomolar activity • It is not toxic to live cells • It has been shown to have some in vivo activity • It is chemically feasible. Specificity of keycompound(s) fromeach leadseriesagainst selectednumber ofreceptors/enzymes • Preliminary PK in vivo(rodent) to establishbenchmark for in vitroSAR • In vitro PK data goodpredictor for in vivoactivity • Its is of course New and Original.
  • 47. Lipinski: « rule of 5 » "In the USAN set we found that the sum of Ns and Os in the molecular formula was greater than 10 in 12% of the compounds. Eleven percent of compounds had a MWT of over 500. Ten percent of compounds had a CLogP larger than 5 (or an MLogP larger than 4.15) and in 8% of compounds the sum of OHs and NHs in the chemical structure was larger than 5. The "rule of 5" states that: poor absorption or permeation is more likely when: A. There are less than 5 H-bond donors (expressed as the sum of OHs and NHs); B. The MWT is less than 500; C. The LogP is less than 5 (or MLogP is < 4.15); D. There are less than 10 H-bond acceptors (expressed as the sum of Ns and Os). Compound classes that are substrates for biological transporters are exceptions to the rule." Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy, Paul J. Feeney "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings":
  • 48. • A quick sketch with ChemDraw, conversion to a 3D structure with Chem3D, and processing by QuikProp, reveals that the problem appears to be poor cell permeability for this relatively polar molecule, with predicted PCaco and PMDCK values near 10 nm/s. • Free alternative (Chemsketch / PreADME)
  • 49. (Celebrex) Methyl in this position makes it a weaker cox-2 inhibitor, but site of metabolic oxidation and ensures an acceptable clearance Drug-like-ness
  • 50. To assist combinatorial chemistry, buy specific compunds
  • 51.
  • 52. Structural Descriptors: (15 descriptors) Molecular Formula, Molecular Weight, Formal Charge, The Number of Rotatable Bonds, The Number of Rigid Bonds, The Number of Rings, The Number of Aromatic Rings, The Number of H Bond Acceptors, The Number of H Bond Donors, The Number of (+) Charged Groups, The Number of (-) Charged Groups, No. single, double, triple, aromatic bonds Topological Descriptors:(350 descriptors) • Topological descriptors on the adjustancy and distance matrix • Count descriptors • Kier & Hall molecular connectivity Indices • Kier Shape Indices • Galvez topological charge Indices • Narumi topological index • Autocorrelation descriptor of atomic masses, atomic polarizability, Pauling electronegativity and van der Waals radius • Information content descriptors • Electrotopological state index (E-state) • Atomic-Level-Based AI topological descriptors Physicochemical Descriptor:(10 descriptors) AlogP98 (calculated logP), SKlogP (calculated logP), SKlogS in pure water (calculated water solubility), SKlogS in buffer system (calculated water solubility),SK vap (calculated vapor pressure), SK bp (calculated boiling point), SK mp (calculated meling point), AMR (calculated molecular refractivity), APOL(calculated polarizability), Water Solvation Free Energy Geometrical Descriptor:(9 descriptors) Topological Polar Surface Area, 2D van der Waals Volume, 2D van der Waals Surface Area, 2D van der Waals Hydrophobic Surface Area, 2D van der Waals Polar Surface Area, 2D van der Waals H-bond Acceptor Surface Area, 2D van der Waals H-bond Donor Surface Area, 2D van der Waals (+) Charged Groups Surface Area, 2D van der Waals (-) Charged Groups Surface Area
  • 53. Drug Discovery: Hit/lead computational approaches • What can you do with these descriptors ? • Cluster entire chemical library – Diversity set – Focused set
  • 54. Drug Discovery: Docking • Structure is known, virtual screening -> docking • Many different approaches – DOCK – FlexX – Glide – GOLD • Including conformational sampling of the ligand • Problem: – host flexibility – solvatation • Example: Bissantz et al. – Hit rate of 10% for single scoring function – Up to 70% with triple scoring (bagging)
  • 55. Drug Discovery: De novo design / rational drug design • Given the target site: • Docking + structure generator • Specialized approach: growing substituent on a core – LUDI – SPROUT – BOMB (biochemical and organic model builder) – SYNOPSIS • Problem is the scoring function which is different for every protein class
  • 56. Drug Discovery: Novel strategies using bio/cheminformatics - HTS ? Chemical space is big (1041) - Biased sets/focussed libraries ->bioinformatics !!! - How ? Use phylogenetics and known structures to define accesible (conserved) functional implicated residues to define small molecule pharmacophores (minimal requirements) - Desciptor search (cheminformatics) to construct/select biased compound set - ensure serendipity by iterative screening of these predesigned sets
  • 57. Drug Discovery Toxigenomics Metabogenomics
  • 58.
  • 59. Drug Discovery: Clinical studies • Preclinical - An early phase of development including initial safety assessment Phase I - Evaluation of clinical pharmacology, usually conducted in volunteers Phase II - Determination of dose and initial evaluation of efficacy, conducted in a small number of patients Phase III - Large comparative study (compound versus placebo and/or established treatment) in patients to establish clinical benefit and safety Phase IV - Post marketing study
  • 60.
  • 61.
  • 62. Drug Discovery & Development: IND filing
  • 64. Pharmacogenomics Predictive/preventive – systems biology
  • 66. Sneak preview Bioinformatics (re)loaded • Relational datamodels – BioSQL (MySQL) • Data Visualisation – Interface • Apache • PHP • Large Scale Statistics – Using R